First In Human open-label dose-escalating trial with expansion cohorts to evaluate safety of Axl specific antibody drug conjugate (HuMax -AXL-ADC) in patients with solid tumors | NYU Langone Health

First In Human open-label dose-escalating trial with expansion cohorts to evaluate safety of Axl specific antibody drug conjugate (HuMax -AXL-ADC) in patients with solid tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Advance Solid Tumors
Age: Between 18 years - 99 years
Gender: Male or Female

Other Inclusion Criteria:

1. Patients with relapsed or refractory non-small cell lung cancer (NSCLC), melanoma, sarcoma 2. Patients who have failed a PD-1/PD-L1 inhibitor 3. Documented progressive disease on or after last prior treatment

You may not be eligible for this study if the following are true:

1. Acute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for at least 4 weeks prior to first IMP administration. 2. Have clinically significant cardiac disease 3. Uncontrolled hypertension defined as systolic blood pressure =160 mmHg and/or diastolic blood pressure =100 mmHg, despite optimal medical management.